This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 3673 |
middle east | 3605 |
east respiratory | 3197 |
syndrome coronavirus | 2714 |
saudi arabia | 1078 |
cov infection | 1042 |
acute respiratory | 687 |
dromedary camels | 652 |
coronavirus infection | 529 |
severe acute | 523 |
south korea | 393 |
respiratory tract | 375 |
mers coronavirus | 312 |
novel coronavirus | 311 |
spike protein | 259 |
risk factors | 253 |
health care | 229 |
human coronavirus | 228 |
public health | 225 |
infection control | 210 |
viral rna | 201 |
cov cases | 197 |
human transmission | 191 |
world health | 189 |
infectious diseases | 188 |
health organization | 181 |
neutralizing antibodies | 178 |
confirmed cases | 178 |
healthcare workers | 170 |
human security | 166 |
united states | 152 |
arabian peninsula | 149 |
cov infections | 148 |
coronavirus infections | 148 |
tg mice | 148 |
lower respiratory | 147 |
mers patients | 142 |
cord uid | 141 |
doc id | 141 |
incubation period | 140 |
dipeptidyl peptidase | 136 |
confirmed mers | 133 |
animal models | 133 |
mouse model | 132 |
hemorrhagic fever | 129 |
upper respiratory | 127 |
binding domain | 122 |
rhesus macaques | 122 |
immune response | 122 |
cov outbreak | 121 |
hong kong | 121 |
clinical features | 119 |
respiratory disease | 117 |
mers cases | 114 |
infectious virus | 112 |
novel human | 110 |
east asia | 109 |
respiratory illness | 109 |
dromedary camel | 107 |
fatality rate | 107 |
sars coronavirus | 107 |
clinical characteristics | 107 |
hospital outbreak | 105 |
symptom onset | 105 |
intensive care | 104 |
respiratory distress | 103 |
control measures | 103 |
closely related | 102 |
united arab | 102 |
arab emirates | 101 |
food safety | 101 |
cov transmission | 101 |
immune responses | 100 |
infectious disease | 98 |
infected patients | 98 |
type i | 98 |
influenza virus | 97 |
critically ill | 97 |
infection prevention | 97 |
epithelial cells | 96 |
respiratory failure | 95 |
viral load | 95 |
severe respiratory | 95 |
viral shedding | 94 |
bronze age | 94 |
coronavirus disease | 93 |
cov patients | 93 |
cov spike | 93 |
distress syndrome | 91 |
arabia middle | 91 |
cov rna | 90 |
systematic review | 90 |
ill patients | 89 |
cov antibodies | 88 |
respiratory symptoms | 87 |
human infection | 87 |
mers outbreak | 86 |
virus infection | 86 |
emerging infectious | 85 |
severe disease | 84 |
chain reaction | 83 |
borne encephalitis | 83 |
east asian | 82 |
avian influenza | 82 |
monoclonal antibodies | 80 |
polymerase chain | 80 |
disease control | 79 |
case fatality | 79 |
mortality rate | 78 |
amino acid | 78 |
monoclonal antibody | 77 |
care workers | 76 |
west nile | 76 |
mers cov | 76 |
mechanical ventilation | 75 |
convalescent plasma | 75 |
ebola virus | 74 |
human cases | 74 |
secondary cases | 74 |
innate immune | 74 |
respiratory infections | 73 |
fever virus | 73 |
descriptive study | 73 |
serum samples | 73 |
clinical trials | 73 |
phylogenetic analysis | 73 |
transgenic mice | 72 |
healthcare settings | 70 |
family cluster | 70 |
emergency room | 69 |
natural foci | 69 |
congo hemorrhagic | 69 |
household contacts | 68 |
close contact | 67 |
viral replication | 67 |
coronavirus spike | 67 |
case definition | 66 |
time reverse | 66 |
within days | 65 |
nosocomial transmission | 65 |
neutralizing antibody | 65 |
vaccine candidates | 65 |
care facilities | 65 |
encephalitis virus | 65 |
coronavirus hku | 64 |
cases reported | 64 |
weight loss | 62 |
coronavirus replication | 61 |
influenza viruses | 60 |
serological study | 60 |
imported case | 60 |
human coronaviruses | 59 |
coronavirus middle | 59 |
cell lines | 59 |
mycophenolic acid | 59 |
healthcare worker | 58 |
middle eastern | 58 |
cell culture | 58 |
care unit | 58 |
common marmoset | 58 |
direct contact | 58 |
viral infection | 58 |
animal model | 58 |
hospitalized patients | 58 |
specific antibodies | 57 |
respiratory viruses | 57 |
infected camels | 57 |
viral loads | 57 |
highly pathogenic | 57 |
cov replication | 57 |
two cases | 56 |
epi isl | 55 |
healthcare facilities | 55 |
human mers | 55 |
nucleocapsid protein | 55 |
suspected cases | 54 |
index case | 54 |
nile virus | 54 |
cov case | 54 |
illness onset | 54 |
clinical course | 54 |
northern eurasia | 53 |
respiratory infection | 53 |
common marmosets | 53 |
lopinavir ritonavir | 53 |
renal failure | 53 |
severe pneumonia | 53 |
previous studies | 53 |
clinical signs | 53 |
severe mers | 52 |
patients infected | 52 |
previously described | 52 |
cohort study | 52 |
statistically significant | 51 |
food poisoning | 51 |
bat coronavirus | 51 |
cov infected | 50 |
may also | 50 |
human monoclonal | 50 |
nasal swabs | 50 |
functional receptor | 50 |
southeast asia | 50 |
high risk | 50 |
study middle | 49 |
spike glycoprotein | 49 |
far east | 49 |
data collection | 49 |
outbreak investigation | 48 |
receptor binding | 47 |
reverse transcription | 47 |
bat coronaviruses | 47 |
wild birds | 47 |
human dpp | 46 |
experimental infection | 46 |
laboratory testing | 46 |
emerging human | 45 |
tract infection | 45 |
reported cases | 45 |
human infections | 45 |
abu dhabi | 45 |
korean outbreak | 44 |
viral infections | 44 |
structural proteins | 44 |
clinical symptoms | 44 |
infection rate | 44 |
among healthcare | 43 |
vero cells | 43 |
large number | 43 |
significantly higher | 43 |
transmission dynamics | 43 |
host cell | 43 |
life insurance | 43 |
virus strains | 43 |
case patients | 43 |
cell entry | 43 |
clinical presentation | 42 |
cov vaccine | 42 |
contact tracing | 42 |
serum antibodies | 42 |
based vaccine | 42 |
nosocomial outbreaks | 42 |
human respiratory | 42 |
risk factor | 42 |
associated coronavirus | 42 |
retrospective cohort | 42 |
strains isolated | 41 |
human betacoronavirus | 41 |
coronavirus mers | 41 |
neutralizing monoclonal | 41 |
experimentally infected | 41 |
mycophenolate mofetil | 41 |
predictive factors | 41 |
high mortality | 41 |
control study | 41 |
coronavirus associated | 40 |
infection among | 40 |
hospital outbreaks | 40 |
personal protective | 40 |
like protease | 40 |
rna viruses | 40 |
close contacts | 40 |
corona virus | 40 |
recovery delay | 40 |
fruit bat | 40 |
global health | 40 |
complete genome | 40 |
high prevalence | 39 |
fi rst | 39 |
present study | 39 |
amino acids | 39 |
first case | 39 |
tested positive | 39 |
genome sequence | 39 |
improves outcome | 39 |
retrospective study | 39 |
suspected mers | 39 |
interferon alfa | 39 |
antibody response | 39 |
dialysis patients | 38 |
observational study | 38 |
healthcare personnel | 38 |
vertebrate hosts | 37 |
imported cases | 37 |
human disease | 37 |
human population | 37 |
south korean | 37 |
one study | 37 |
virus disease | 37 |
coronavirus oc | 37 |
protective equipment | 37 |
disease severity | 37 |
respiratory samples | 37 |
laboratory findings | 37 |
bubonic plague | 37 |
neutralising antibodies | 37 |
median age | 37 |
associated outbreak | 36 |
zoonotic transmission | 36 |
mva mers | 36 |
infected animals | 36 |
near east | 36 |
japanese encephalitis | 36 |
older age | 36 |
converting enzyme | 36 |
immune system | 36 |
arthropod vectors | 36 |
tertiary care | 36 |
comparative serological | 36 |
confirmed case | 36 |
performed using | 36 |
disease outbreak | 36 |
sporadic cases | 35 |
united nations | 35 |
clinical aspects | 35 |
icu admission | 35 |
therapeutic options | 35 |
jamaican fruit | 35 |
fruit bats | 35 |
vaccinia virus | 35 |
even though | 35 |
family members | 35 |
open reading | 35 |
infected mice | 35 |
asymptomatic cases | 35 |
united kingdom | 35 |
increased risk | 35 |
north america | 34 |
cov virus | 34 |
cellular immune | 34 |
clinical outcomes | 34 |
chikungunya virus | 34 |
vaccine development | 34 |
human neutralizing | 34 |
laboratory confirmation | 34 |
cov antigen | 34 |
phylogenetic tree | 34 |
chadox mers | 34 |
clinical trial | 34 |
first imported | 34 |
days post | 33 |
lung disease | 33 |
gastrointestinal symptoms | 33 |
travel history | 33 |
reported mers | 33 |
mers coronaviruses | 33 |
insurance companies | 33 |
gene expression | 33 |
fatal cases | 33 |
coronavirus transmission | 33 |
western siberia | 33 |
study design | 33 |
membrane fusion | 33 |
data gaps | 33 |
coronavirus neutralising | 33 |
nonhuman primates | 33 |
virus replication | 33 |
healthcare setting | 33 |
protective efficacy | 32 |
authors declare | 32 |
neutralising serum | 32 |
clinical manifestations | 32 |
infect dis | 32 |
tissue culture | 32 |
risk assessment | 32 |
case report | 32 |
rift valley | 32 |
person transmission | 32 |
coronavirus receptor | 32 |
slaughterhouse workers | 32 |
type ii | 32 |
astrakhan region | 32 |
prediction model | 31 |
mortality rates | 31 |
interstitial pneumonia | 31 |
high levels | 31 |
genetic diversity | 31 |
eastern respiratory | 31 |
mouse models | 31 |
coronavirus outbreak | 31 |
patients received | 31 |
coronavirus pneumonia | 31 |
acute renal | 31 |
pcr testing | 31 |
respiratory coronavirus | 31 |
camels middle | 31 |
insurance market | 31 |
total number | 31 |
severe cases | 31 |
transcription polymerase | 31 |
ticks collected | 31 |
domestic animals | 31 |
syndrome outbreak | 31 |
cov strains | 31 |
bronchial epithelial | 30 |
dna vaccine | 30 |
another study | 30 |
animal species | 30 |
sars outbreak | 30 |
care hospital | 30 |
symptomatic cases | 30 |
antibody responses | 30 |
severe middle | 30 |
case reports | 30 |
tract infections | 30 |
logistic regression | 30 |
clinical management | 30 |
cell line | 30 |
medical center | 30 |
international catalogue | 30 |
diabetes mellitus | 29 |
pneumonia development | 29 |
inflammatory cells | 29 |
clinical description | 29 |
coronavirus vaccine | 29 |
arabia mers | 29 |
viral respiratory | 29 |
single patient | 29 |
organ failure | 29 |
human dipeptidyl | 29 |
alveolar damage | 29 |
based vaccines | 29 |
fatal case | 29 |
spreading events | 29 |
affected countries | 29 |
transgenic mouse | 29 |
modified vaccinia | 29 |
respiratory specimens | 29 |
new coronavirus | 29 |
cov rbd | 29 |
infectious bronchitis | 29 |
virus infections | 28 |
tract samples | 28 |
old tg | 28 |
accessory proteins | 28 |
primorsky krai | 28 |
genetic characterization | 28 |
antiviral activity | 28 |
control practices | 28 |
natural reservoir | 28 |
protective immunity | 28 |
medical conditions | 28 |
genomic characterization | 28 |
saudi ministry | 28 |
korea middle | 28 |
bovine coronavirus | 28 |
tcid ml | 28 |
health authorities | 28 |
described previously | 28 |
animal reservoir | 28 |
high viral | 28 |
emergency department | 28 |
mers infection | 28 |
supportive care | 28 |
human middle | 28 |
lung injury | 28 |
camel contact | 28 |
day post | 28 |
respiratory diseases | 28 |
dis doi | 27 |
patients admitted | 27 |
cov epidemic | 27 |
competing interests | 27 |
biosafety level | 27 |
better understand | 27 |
interferon therapy | 27 |
mildly symptomatic | 27 |
antiviral agents | 27 |
coronavirus antibodies | 27 |
generating procedures | 27 |
geographic distribution | 27 |
virological analysis | 27 |
coronavirus emc | 27 |
outbreak news | 27 |
throat swabs | 27 |
phase i | 27 |
first reported | 27 |
years old | 27 |
genome sequences | 27 |
nasal swab | 27 |
camel mers | 27 |
food security | 27 |
contact investigation | 27 |
acquired pneumonia | 27 |
related viruses | 27 |
mers case | 27 |
coronavirus neutralizing | 27 |
potential risk | 27 |
available data | 27 |
hospital transmission | 27 |
germ warfare | 26 |
asymptomatic infection | 26 |
days prior | 26 |
viral titers | 26 |
camel herd | 26 |
cov causes | 26 |
virus isolation | 26 |
first isolated | 26 |
volga delta | 26 |
postexposure efficacy | 26 |
high level | 26 |
case series | 26 |
virus transmission | 26 |
current situation | 26 |
clinical data | 26 |
hajj pilgrims | 26 |
cov vaccines | 26 |
asian countries | 26 |
acute kidney | 26 |
high fatality | 26 |
mers outbreaks | 26 |
virus ankara | 26 |
mean age | 26 |
new zealand | 25 |
mg ml | 25 |
nasal discharge | 25 |
lung tissue | 25 |
nervous system | 25 |
animal health | 25 |
care settings | 25 |
study showed | 25 |
two groups | 25 |
livestock species | 25 |
renal replacement | 25 |
primate model | 25 |
host species | 25 |
international committee | 25 |
emerging pathogens | 25 |
emerging coronaviruses | 25 |
strain leiv | 25 |
lung pathology | 25 |
cov challenge | 25 |
valley fever | 25 |
cell responses | 25 |
hand hygiene | 25 |
fi gure | 25 |
factors associated | 25 |
i interferon | 25 |
among patients | 25 |
cause severe | 25 |
camel milk | 25 |
foodborne disease | 25 |
genome sequencing | 25 |
multiorgan failure | 24 |
investigation team | 24 |
virus shedding | 24 |
confi rmed | 24 |
food handlers | 24 |
recent study | 24 |
virus excretion | 24 |
ii pneumocytes | 24 |
including deaths | 24 |
host cells | 24 |
results suggest | 24 |
replacement therapy | 24 |
bat species | 24 |
healthcare facility | 24 |
new virus | 24 |
time pcr | 24 |
primary cases | 24 |
antiviral therapy | 24 |
caspian sea | 24 |
respiratory syncytial | 24 |
borne viruses | 24 |
stranded rna | 24 |
viral entry | 24 |
plaque reduction | 24 |
haemorrhagic fever | 24 |
center experience | 24 |
early stage | 24 |
combination therapy | 23 |
inhibits mers | 23 |
endothelial cells | 23 |
clinical specimens | 23 |
indirect contact | 23 |
viral genome | 23 |
canary islands | 23 |
newly discovered | 23 |
creative commons | 23 |
polyprotein precursor | 23 |
major livestock | 23 |
control groups | 23 |
reproduction number | 23 |
viruses isolated | 23 |
camel sera | 23 |
general population | 23 |
transmission within | 23 |
medical care | 23 |
cell cultures | 23 |
reading frame | 23 |
median time | 23 |
central asia | 23 |
viral antigen | 23 |
virus isolated | 23 |
kidney injury | 23 |
primary middle | 23 |
syncytial virus | 23 |
much higher | 23 |
epidemiological investigation | 23 |
illness caused | 23 |
chest pain | 22 |
infected rhesus | 22 |
epidemiological data | 22 |
time series | 22 |
family contacts | 22 |
subunit vaccine | 22 |
confidence interval | 22 |
transmission among | 22 |
bl mice | 22 |
host factors | 22 |
inflammatory cytokines | 22 |
nonstructural proteins | 22 |
virus neutralisation | 22 |
rna virus | 22 |
insectivorous bats | 22 |
ce serocomplex | 22 |
target cells | 22 |
human airway | 22 |
viral diagnosis | 22 |
tested negative | 22 |
severe illness | 22 |
critical care | 22 |
animal studies | 22 |
syndrome middle | 22 |
significant differences | 22 |
important role | 22 |
healthcare systems | 22 |
spike gene | 22 |
cov pathogenesis | 22 |
vaccine candidate | 22 |
ixodidae ticks | 22 |
domestic livestock | 22 |
coronavirus causes | 22 |
diff erent | 22 |
also known | 22 |
discovered coronavirus | 22 |
eastern mediterranean | 21 |
tracheal aspirates | 21 |
literature update | 21 |
cov neutralizing | 21 |
sea peoples | 21 |
ribavirin improves | 21 |
based study | 21 |
genomic rna | 21 |
first mers | 21 |
mice showed | 21 |
treatment options | 21 |
small number | 21 |
rna polymerase | 21 |
social media | 21 |
medical countermeasures | 21 |
genbank accession | 21 |
asymptomatic mers | 21 |
membrane oxygenation | 21 |
one patient | 21 |
spectrum antiviral | 21 |
associated outbreaks | 21 |
protease inhibitors | 21 |
potent neutralization | 21 |
bronchitis virus | 21 |
swab samples | 21 |
identifi ed | 21 |
molecular epidemiology | 21 |
medical records | 21 |
comparative analysis | 21 |
several studies | 21 |
nonhuman primate | 21 |
pregnant women | 21 |
also found | 21 |
interferon beta | 21 |
study group | 21 |
mortality risk | 21 |
vitro studies | 21 |
tahyna virus | 21 |
tg mouse | 21 |
samples collected | 21 |
hdpp transgenic | 21 |
bronchoalveolar lavage | 21 |
like viruses | 21 |
coronavirus species | 21 |
korea outbreak | 21 |
renal disease | 21 |
also reported | 21 |
least one | 21 |
fatality rates | 21 |
investigation middle | 20 |
asian tigers | 20 |
human primates | 20 |
affected region | 20 |
bhanja virus | 20 |
camel coronavirus | 20 |
single dose | 20 |
related patients | 20 |
higher risk | 20 |
virus entry | 20 |
environmental conditions | 20 |
high case | 20 |
dpp receptor | 20 |
causes lethal | 20 |
coronavirus seroprevalence | 20 |
operating room | 20 |
two mers | 20 |
cov outbreaks | 20 |
novel middle | 20 |
pegylated interferon | 20 |
review board | 20 |
times higher | 20 |
although mers | 20 |
envelope protein | 20 |
negative pressure | 20 |
mers patient | 20 |
new york | 20 |
reduces virus | 20 |
african countries | 20 |
virus taxonomy | 20 |
vaccine reduces | 20 |
etiological agent | 20 |
electron microscopy | 20 |
institutional review | 20 |
mers vaccines | 20 |
serologic testing | 20 |
heart disease | 20 |
three camel | 20 |
sars patients | 20 |
virus load | 20 |
copyright holder | 20 |
one health | 20 |
crystal structure | 20 |
infected patient | 20 |
viral spike | 20 |
pipistrellus bat | 20 |
previously reported | 20 |
median incubation | 19 |
reverse transcriptase | 19 |
interim guidance | 19 |
central nervous | 19 |
healthcare system | 19 |
pcr assay | 19 |
unrecognized asymptomatic | 19 |
infections among | 19 |
lymph nodes | 19 |
diffuse alveolar | 19 |
coronavirus using | 19 |
two patients | 19 |
time rt | 19 |
southeastern asia | 19 |
patient exposure | 19 |
descriptive genomic | 19 |
pediatric patients | 19 |
different countries | 19 |
nipah virus | 19 |
rhesus macaque | 19 |
extracorporeal membrane | 19 |
underlying medical | 19 |
dpp expression | 19 |
survival rates | 19 |
transient lower | 19 |
attack rate | 19 |
primary human | 19 |
european countries | 19 |
serological evidence | 19 |
mice infected | 19 |
cov among | 19 |
coronavirus among | 19 |
camels mers | 19 |
ultrastructural findings | 19 |
old man | 19 |
respiratory secretions | 19 |
sore throat | 19 |
common pipistrelle | 19 |
human beings | 19 |
pcr assays | 19 |
coronavirus illness | 19 |
publicly available | 19 |
pandemic influenza | 19 |
cov shedding | 19 |
genomic study | 19 |
sandfly fever | 19 |
avian coronaviruses | 19 |
vaccinated group | 19 |
among camels | 19 |
human covs | 19 |
horseshoe bats | 19 |
betacoronavirus lineage | 19 |
human antibodies | 18 |
among humans | 18 |
instillation group | 18 |
syndrome corona | 18 |
disease prevention | 18 |
potential conflicts | 18 |
index patient | 18 |
developing countries | 18 |
like virus | 18 |
late bronze | 18 |
treatment group | 18 |
inoculated dromedary | 18 |
respiratory pathogens | 18 |
nasopharyngeal swabs | 18 |
pandemic potential | 18 |
among children | 18 |
serocomplex viruses | 18 |
urgently needed | 18 |
see note | 18 |
associated middle | 18 |
first cases | 18 |
relatively low | 18 |
tract specimens | 18 |
body temperature | 18 |
full genome | 18 |
dengue virus | 18 |
antibody titers | 18 |
spike proteins | 18 |
whole genome | 18 |
acute middle | 18 |
infectious peritonitis | 18 |
higher viral | 18 |
host proteases | 18 |
ct values | 18 |
environmental contamination | 18 |
prospective study | 18 |
post inoculation | 18 |
like particles | 18 |
clinical studies | 18 |
likely unrecognized | 18 |
better understanding | 18 |
studies showed | 18 |
health response | 18 |
sequence analysis | 18 |
three years | 18 |
comparative study | 18 |
nairovirus genus | 18 |
human rights | 18 |
body weight | 18 |
medical city | 18 |
viral proteins | 18 |
infections related | 18 |
mild case | 18 |
attack rates | 18 |
abdominal pain | 18 |
fully human | 18 |
uukuniemi virus | 17 |
dpp binding | 17 |
terminal domain | 17 |
cov antibody | 17 |
two different | 17 |
fusion protein | 17 |
pathological changes | 17 |
previous reports | 17 |
russian plain | 17 |
early stages | 17 |
protein induces | 17 |
room temperature | 17 |
rapid generation | 17 |
european part | 17 |
close relative | 17 |
significantly lower | 17 |
transmission routes | 17 |
chikungunya fever | 17 |
serological testing | 17 |
cov sequences | 17 |
mouse dpp | 17 |
south africa | 17 |
cov activity | 17 |
pathogenic avian | 17 |
mg kg | 17 |
among different | 17 |
cov genome | 17 |
subunit vaccines | 17 |
ex vivo | 17 |
cov seropositivity | 17 |
cases may | 17 |
inhibit mers | 17 |
among dromedary | 17 |
study mers | 17 |
secondary transmission | 17 |
genus betacoronavirus | 17 |
index cases | 17 |
limited number | 17 |
linked immunosorbent | 17 |
studies reported | 17 |
egyptian fruit | 17 |
intestinal tract | 17 |
diagnostic tests | 17 |
treat middle | 17 |
risk prediction | 17 |
hittite empire | 17 |
pandemic risk | 17 |
viral diseases | 17 |
exposed patients | 17 |
lethal pneumonia | 17 |
nucleic acid | 17 |
odds ratio | 17 |
surveillance systems | 17 |
genome analysis | 17 |
study period | 17 |
bat origin | 17 |
nosocomial outbreak | 17 |
disease surveillance | 17 |
many countries | 17 |
humanized mouse | 17 |
eastern countries | 17 |
feline infectious | 17 |
infected individuals | 17 |
first detected | 17 |
uukuniemi group | 17 |
length genome | 17 |
infected dromedary | 17 |
challenged mice | 17 |
cov viral | 17 |
epidemic potential | 17 |
therapeutic agents | 17 |
saudi arabian | 17 |
large outbreak | 17 |
cov strain | 17 |
emc strain | 17 |
viral titer | 17 |
cases among | 17 |
central europe | 17 |
iu ml | 17 |
swab specimens | 17 |
study clinical | 17 |
control group | 16 |
remains unclear | 16 |
human isolates | 16 |
hospital patients | 16 |
clinical presentations | 16 |
airborne transmission | 16 |
large outbreaks | 16 |
symptomatic patients | 16 |
heptad repeat | 16 |
lactate dehydrogenase | 16 |
sequence identity | 16 |
made available | 16 |
higher mers | 16 |
intranasal inoculation | 16 |
preventive measures | 16 |
five patients | 16 |
control guidelines | 16 |
pcr tests | 16 |
syncytial cells | 16 |
lung tissues | 16 |
included studies | 16 |
bunyaviridae family | 16 |
patients may | 16 |
negative control | 16 |
omsk hemorrhagic | 16 |
plasma therapy | 16 |
antiviral response | 16 |
specific antiviral | 16 |
measles virus | 16 |
low levels | 16 |
neutralization test | 16 |
mass gatherings | 16 |
molecular basis | 16 |
fatal mers | 16 |
supplementary material | 16 |
samsung medical | 16 |
first confirmed | 16 |
first identified | 16 |
positive results | 16 |
neighboring countries | 16 |
live virus | 16 |
aerosol group | 16 |
sample size | 16 |
coronavirus study | 16 |
pipistrelle bat | 16 |
two strains | 16 |
accession number | 16 |
cov emc | 16 |
broad spectrum | 16 |
treatment strategies | 16 |
air travel | 16 |
camel population | 16 |
outbreak study | 16 |
zoonotic origin | 16 |
randomized controlled | 16 |
million people | 16 |
alveolar macrophages | 16 |
neutralisation assays | 16 |
respiratory virus | 16 |
vitro activity | 16 |
outbreak outside | 16 |
supplementary table | 16 |
dhabi emirate | 16 |
lethal disease | 16 |
bactrian camels | 16 |
mouse hepatitis | 16 |
septic shock | 16 |
camel herds | 16 |
statistical analyses | 16 |
phylogenetic analyses | 16 |
dendritic cells | 16 |
market workers | 16 |
antiviral treatment | 16 |
results showed | 16 |
related deaths | 16 |
infectious agents | 16 |
eastern europe | 16 |
nucleotide sequence | 16 |
relatively high | 16 |
causes transient | 16 |
long time | 16 |
mild respiratory | 16 |
continuous variables | 16 |
retrospective studies | 16 |
proinflammatory cytokines | 16 |
global alert | 16 |
natural reservoirs | 16 |
international license | 16 |
antiviral drugs | 16 |
significant difference | 16 |
acid sequence | 16 |
causative agent | 15 |
two studies | 15 |
reservoir host | 15 |
world war | 15 |
novel humanized | 15 |
nasopharyngeal swab | 15 |
southern part | 15 |
cov spread | 15 |
live mers | 15 |
will help | 15 |
genetic analysis | 15 |
rapid response | 15 |
fusion inhibitor | 15 |
viral transmission | 15 |
mild symptoms | 15 |
severe lung | 15 |
growth rate | 15 |
positive control | 15 |
referral hospital | 15 |
epidemiological link | 15 |
day mortality | 15 |
candidate vaccine | 15 |
copies ml | 15 |
exceptionally potent | 15 |
patient contact | 15 |
sars cov | 15 |
climate change | 15 |
sialic acid | 15 |
getah virus | 15 |
ivanovsky institute | 15 |
life cycle | 15 |
korean society | 15 |
nonstructural protein | 15 |
controlled trial | 15 |
innate antiviral | 15 |
epidemiological characteristics | 15 |
plaque assay | 15 |
species restriction | 15 |
cov may | 15 |
polyclonal antibodies | 15 |
study reported | 15 |
nonfatal cases | 15 |
cov population | 15 |
transmission potential | 15 |
spectrum antivirals | 15 |
emerging novel | 15 |
data analysis | 15 |
old male | 15 |
aspartate aminotransferase | 15 |
infected cells | 15 |
wild animals | 15 |
near future | 15 |
risk countries | 15 |
isolation room | 15 |
originally isolated | 15 |
epidemiological analysis | 15 |
including sars | 15 |
phase ii | 15 |
prospective descriptive | 15 |
cov isolates | 15 |
nasal turbinates | 15 |
inflammatory cell | 15 |
immunosorbent assay | 15 |
community acquired | 15 |
dna vaccines | 15 |
novel betacoronavirus | 15 |
final manuscript | 15 |
infection caused | 15 |
recombinant receptor | 15 |
camel populations | 15 |
analysis showed | 15 |
infection middle | 15 |
large numbers | 15 |
epidemiological findings | 15 |
protein microarray | 15 |
coronavirus genome | 15 |
foodborne illnesses | 15 |
infection clinical | 15 |
differential diagnosis | 15 |
much lower | 15 |
southern china | 15 |
tohuman transmission | 15 |
commons license | 15 |
eastern siberia | 15 |
small animal | 15 |
czech republic | 15 |
emerging coronavirus | 15 |
granted medrxiv | 15 |
analysis based | 15 |
severely ill | 15 |
author funder | 15 |
foodborne illness | 15 |
febrile illness | 15 |
current knowledge | 15 |
study also | 15 |
bat sars | 15 |
risk posed | 15 |
epidemiological outbreak | 15 |
serologic evidence | 15 |
staphylococcus aureus | 15 |
outbreak following | 15 |
human cells | 15 |
health department | 15 |
pseudotyped mers | 15 |
buffered saline | 15 |
blood donors | 15 |
adaptive evolution | 15 |
rectal swabs | 15 |
adenosine deaminase | 15 |
pseudoparticle virus | 15 |
interhuman transmissibility | 15 |
specific human | 15 |
several limitations | 15 |
retrospective investigation | 15 |
whether mers | 14 |
chest radiographs | 14 |
occupational exposure | 14 |
secondary infections | 14 |
day survival | 14 |
viral challenge | 14 |
east area | 14 |
triple combination | 14 |
renal syndrome | 14 |
signifi cant | 14 |
risk close | 14 |
underlying diseases | 14 |
emergency departments | 14 |
com scientificreports | 14 |
health security | 14 |
case studies | 14 |
cell infiltration | 14 |
assays reveal | 14 |
one case | 14 |
viral species | 14 |
sars epidemic | 14 |
mosquitoes collected | 14 |
small intestine | 14 |
virus circulation | 14 |
currently available | 14 |
also detected | 14 |
acute lung | 14 |
organ damage | 14 |
three days | 14 |
animal care | 14 |
cov receptor | 14 |
new world | 14 |
causes severe | 14 |
antiviral regimen | 14 |
major outbreak | 14 |
cell membrane | 14 |
coronavirus antibody | 14 |
respiratory viral | 14 |
using microneutralisation | 14 |
one strain | 14 |
global spread | 14 |
genetic recombination | 14 |
infectious mers | 14 |
uriae ticks | 14 |
alveolar epithelial | 14 |
peptidase iv | 14 |
early detection | 14 |
emerging respiratory | 14 |
test results | 14 |
early diagnosis | 14 |
key role | 14 |
first time | 14 |
cov neutralising | 14 |
gene source | 14 |
membrane protein | 14 |
age groups | 14 |
sectional study | 14 |
sense rna | 14 |
protein expression | 14 |
disease associated | 14 |
financial support | 14 |
respiratory droplets | 14 |
naturally infected | 14 |
swine influenza | 14 |
fatal outcome | 14 |
multiple organ | 14 |
results indicate | 14 |
global public | 14 |
airborne precautions | 14 |
emerging infection | 14 |
statistical analysis | 14 |
passive immunotherapy | 14 |
king abdulaziz | 14 |
intermediate host | 14 |
igg antibodies | 14 |
insurance markets | 14 |
like disease | 14 |
three segments | 14 |
different environmental | 14 |
pneumonia patients | 14 |
including mers | 14 |
male sex | 14 |
contaminated food | 14 |
hospital admission | 14 |
sri lanka | 14 |
receptor cd | 14 |
tissue tropism | 14 |
russian federation | 14 |
prototypical strain | 14 |
transmissible gastroenteritis | 14 |
endoplasmic reticulum | 14 |
arabia clinical | 14 |
transmission characteristics | 14 |
per year | 14 |
also showed | 14 |
infected people | 14 |
pilgrims returning | 14 |
urgent need | 13 |
lymph node | 13 |
two decades | 13 |
two years | 13 |
comparator group | 13 |
literature review | 13 |
murine coronavirus | 13 |
combination antiviral | 13 |
interferon alpha | 13 |
nasal secretions | 13 |
human primate | 13 |
infection isolation | 13 |
severe clinical | 13 |
economic growth | 13 |
transmission chains | 13 |
oc antigen | 13 |
family bunyaviridae | 13 |
ct value | 13 |
globally reported | 13 |
emerging middle | 13 |
international spread | 13 |
referral center | 13 |
high degree | 13 |
initial rrt | 13 |
infect humans | 13 |
syndrome coronaviruses | 13 |
emerg infect | 13 |
virus isolates | 13 |
artibeus jamaicensis | 13 |
top eight | 13 |
antiviral compounds | 13 |
hepatitis virus | 13 |
first patient | 13 |
viruses among | 13 |
human populations | 13 |
corticosteroid therapy | 13 |
potential therapeutic | 13 |
bovine serum | 13 |
mild upper | 13 |
calculated using | 13 |
mucosal immunity | 13 |
international health | 13 |
different regions | 13 |
kidney disease | 13 |
camelus dromedaries | 13 |
droplet precautions | 13 |
two viruses | 13 |
lesser extent | 13 |
surveillance biases | 13 |
air force | 13 |
national institute | 13 |
macaque model | 13 |
marburg virus | 13 |
host immune | 13 |
orf ab | 13 |
blood pressure | 13 |
asymptomatic infections | 13 |
like coronavirus | 13 |
cytopathic effects | 13 |
specific anti | 13 |
laboratory confirmed | 13 |
clinical outcome | 13 |
acute pneumonia | 13 |
disease progression | 13 |
standard deviation | 13 |
cov inoculation | 13 |
least two | 13 |
rna genome | 13 |
arboviral zoonoses | 13 |
burkina faso | 13 |
enhanced ppe | 13 |
among hcws | 13 |
food production | 13 |
cell response | 13 |
camel exposures | 13 |
european centre | 13 |
type smallpox | 13 |
viral pathogenesis | 13 |
outbreak hospital | 13 |
netherland dwarf | 13 |
infection may | 13 |
borne phleboviruses | 13 |
case study | 13 |
viral antigens | 13 |
coronavirus nl | 13 |
positive cases | 13 |
transmission events | 13 |
cov remains | 13 |
highest risk | 13 |
ninth report | 13 |
iron age | 13 |
among pilgrims | 13 |
tissue samples | 13 |
african bat | 13 |
river delta | 13 |
organ cultures | 13 |
like coronaviruses | 13 |
camelus dromedarius | 13 |
accessory protein | 13 |
serological analysis | 13 |
many years | 13 |
human lungs | 13 |
treatment outcomes | 13 |
data suggest | 13 |
dwarf rabbits | 13 |
tickborne encephalitis | 13 |
sick men | 13 |
war ii | 13 |
hdpp expression | 13 |
human cell | 13 |
transcriptase polymerase | 13 |
coronavirus rna | 13 |
palm civets | 13 |
potential mers | 13 |
communicable diseases | 13 |
first two | 13 |
high proportion | 13 |
viruses related | 13 |
novel viruses | 13 |
mg dl | 13 |
viral particles | 13 |
retrospective analysis | 13 |
pcr results | 13 |
previous study | 13 |
hyalomma marginatum | 13 |
graphpad prism | 13 |
north africa | 13 |
therapeutic efficacy | 13 |
data show | 13 |
east africa | 13 |
cycle threshold | 13 |
tylonycteris bat | 13 |
mice treated | 13 |
reading frames | 13 |
fully understood | 13 |
reported case | 13 |
antigenic relationships | 13 |
low level | 13 |
powassan virus | 13 |
prior probability | 13 |
transmission occurred | 12 |
genus nairovirus | 12 |
rate among | 12 |
breath samples | 12 |
specific igg | 12 |
animal experiments | 12 |
doctor shopping | 12 |
years later | 12 |
imported middle | 12 |
lung lesions | 12 |
cov genomes | 12 |
health regulations | 12 |
betacoronavirus causing | 12 |
considered statistically | 12 |
common symptoms | 12 |
general hospital | 12 |
death among | 12 |
high latitudes | 12 |
feline coronavirus | 12 |
female ratio | 12 |
medrxiv preprint | 12 |
days later | 12 |
korea mers | 12 |
clinical disease | 12 |
chronic lung | 12 |
human isolate | 12 |
quality assessment | 12 |
among imported | 12 |
viral pathogens | 12 |
vasopressor therapy | 12 |
interpreted data | 12 |
protein rbd | 12 |
mild disease | 12 |
underlying disease | 12 |
short time | 12 |
insurance products | 12 |
north korea | 12 |
epithelial cell | 12 |
pediatric cases | 12 |
respiratory illnesses | 12 |
additional file | 12 |
studies suggest | 12 |
cov antigens | 12 |
recent years | 12 |
underlying comorbidities | 12 |
clinical practice | 12 |
human receptor | 12 |
widespread infection | 12 |
interim case | 12 |
take place | 12 |
serological studies | 12 |
demographic characteristics | 12 |
envelope glycoproteins | 12 |
years ago | 12 |
highly immunogenic | 12 |
african mers | 12 |
humanized neutralizing | 12 |
california encephalitis | 12 |
several days | 12 |
common cold | 12 |
geographical distribution | 12 |
reduction neutralization | 12 |
nasal cavity | 12 |
medical research | 12 |
demographic data | 12 |
cov jordan | 12 |
adaptive immune | 12 |
human bronchial | 12 |
syndrome clinical | 12 |
exponential growth | 12 |
host innate | 12 |
biological properties | 12 |
cov treatment | 12 |
preliminary report | 12 |
zealand rabbits | 12 |
conspecific virus | 12 |
possible cause | 12 |
found among | 12 |
year period | 12 |
many cases | 12 |
cov pcr | 12 |
control precautions | 12 |
beta interferon | 12 |
induces severe | 12 |
cov nucleocapsid | 12 |
one hand | 12 |
recent outbreak | 12 |
clinical findings | 12 |
serologic responses | 12 |
human clinical | 12 |
antibody levels | 12 |
syndrome virus | 12 |
i ifn | 12 |
west africa | 12 |
posterior probability | 12 |
dry cough | 12 |
remains unknown | 12 |
regression analysis | 12 |
since immigration | 12 |
virus vaccine | 12 |
serum sample | 12 |
laboratory results | 12 |
negative results | 12 |
similar results | 12 |
state collection | 12 |
new arbovirus | 12 |
protein gene | 12 |
humoral immune | 12 |
coronavirus fusion | 12 |
cd monoclonal | 12 |
may occur | 12 |
cov detection | 12 |
civil society | 12 |
hdpp tg | 12 |
fi nal | 12 |
disease outbreaks | 12 |
blood cell | 12 |
severe covid | 12 |
taken together | 12 |
deep sequencing | 12 |
updated information | 12 |
among mers | 12 |
flow cytometry | 12 |
wide range | 12 |
healthcare professionals | 12 |
positive test | 12 |
epidemiological studies | 12 |
raw milk | 12 |
using real | 12 |
secondary infection | 12 |
emergency committee | 12 |
cleavage site | 12 |
likely source | 12 |
patients presenting | 12 |
fecal samples | 12 |
zone iv | 12 |
operating rooms | 12 |
influenza infection | 12 |
acid sequences | 12 |
emerging diseases | 12 |
target cell | 12 |
bat cov | 12 |
acquired cases | 12 |
oxygen saturation | 12 |
underlying conditions | 12 |
higher levels | 12 |
insurance industry | 12 |
study found | 12 |
two human | 12 |
western countries | 12 |
coronavirus date | 12 |
imported mers | 12 |
khabarovsk krai | 12 |
categorical variables | 12 |
pregnant woman | 12 |
large tertiary | 12 |
korean mers | 12 |
apache ii | 12 |
fetal bovine | 11 |
current study | 11 |
also observed | 11 |
statistical significance | 11 |
data available | 11 |
kul virus | 11 |
arab middle | 11 |
become infected | 11 |
protective effect | 11 |
cov diagnosis | 11 |
viral pneumonia | 11 |
i clinical | 11 |
commander islands | 11 |
east asians | 11 |
including certain | 11 |
single hospital | 11 |
southern taiga | 11 |
seasonal influenza | 11 |
binding site | 11 |
western part | 11 |
time points | 11 |
may lead | 11 |
core domain | 11 |
chest ct | 11 |
coronavirus human | 11 |
dromedary wnv | 11 |
national health | 11 |
glycoproteins gn | 11 |
international severe | 11 |
multiple generations | 11 |
sputum samples | 11 |
global summary | 11 |
time point | 11 |
cov testing | 11 |
outbreak members | 11 |
eight emerging | 11 |
side effects | 11 |
food outlets | 11 |
sick man | 11 |
days vs | 11 |
social distancing | 11 |
current status | 11 |
volga river | 11 |
tract tissues | 11 |
tissue distribution | 11 |
causing sars | 11 |
coronavirus vaccines | 11 |
generation time | 11 |
recombinant modified | 11 |
donor rabbits | 11 |
authors read | 11 |
ace receptor | 11 |
signifi cantly | 11 |
findings may | 11 |
varying degrees | 11 |
elevated ast | 11 |
east region | 11 |
without tpa | 11 |
vaccine induces | 11 |
blood samples | 11 |
camels antibodies | 11 |
health careeassociated | 11 |
financial services | 11 |
mice expressing | 11 |
associated infections | 11 |
supportive treatment | 11 |
antibody titres | 11 |
icu patients | 11 |
protease inhibitor | 11 |
randomized clinical | 11 |
host response | 11 |
arabia evidence | 11 |
safe food | 11 |
another zoonotic | 11 |
ricinus ticks | 11 |
molecular characterization | 11 |
illness associated | 11 |
congo haemorrhagic | 11 |
largest outbreak | 11 |
independent risk | 11 |
limited data | 11 |
studies using | 11 |
final outcome | 11 |
epidemiologic data | 11 |
intermediate hosts | 11 |
virus clearance | 11 |
developed pneumonia | 11 |
saharan africa | 11 |
associated cases | 11 |
molecule inhibitors | 11 |
cov activities | 11 |
survival rate | 11 |
others viruses | 11 |
table shows | 11 |
neutralizing activity | 11 |
etiologically linked | 11 |
epidemiological assessment | 11 |
three viruses | 11 |
south america | 11 |
cell types | 11 |
major role | 11 |
main operating | 11 |
health systems | 11 |
relative risk | 11 |
technical meeting | 11 |
sustained human | 11 |
case control | 11 |
european union | 11 |
camel interactions | 11 |
ixodes uriae | 11 |
fraction yield | 11 |
infected dromedaries | 11 |
zoonotic betacoronavirus | 11 |
international collaboration | 11 |
crucial role | 11 |
vaccines based | 11 |
human vaccine | 11 |
recombination events | 11 |
cov entry | 11 |
reduced viral | 11 |
serum specimens | 11 |
viral etiology | 11 |
contact precautions | 11 |
final version | 11 |
also described | 11 |
transcription pcr | 11 |
common ancestor | 11 |
camels may | 11 |
animal reservoirs | 11 |
potent inhibitors | 11 |
pulmonary disease | 11 |
viral excretion | 11 |
factors related | 11 |
landscape belts | 11 |
case clusters | 11 |
active surveillance | 11 |
airway epithelium | 11 |
well plates | 11 |
initial outbreak | 11 |
arbovirus isolated | 11 |
first week | 11 |
significantly associated | 11 |
syrian hamsters | 11 |
receptor dpp | 11 |
inhibitors targeting | 11 |
strongly inhibited | 11 |
symptomatic mers | 11 |
four patients | 11 |
arboviruses including | 11 |
coronavirus nucleocapsid | 11 |
replication induces | 11 |
vaccine approaches | 11 |
cov middle | 11 |
growth rates | 11 |
vitro cytopathology | 11 |
viral transport | 11 |
related cases | 11 |
dry ice | 11 |
genome fraction | 11 |
patients requiring | 11 |
korea clinical | 11 |
hajj pilgrimage | 11 |
study hospital | 11 |
nile fever | 11 |
log reduction | 11 |
new drug | 11 |
air sample | 11 |
including diabetes | 11 |
secondary mers | 11 |
virus spread | 11 |
peripheral blood | 11 |
cov patient | 11 |
clinical picture | 11 |
transmission risk | 11 |
based subunit | 11 |
genetic variation | 11 |
disease pathogenesis | 11 |
hae cultures | 11 |
retrieved articles | 11 |
dependent rna | 11 |
cov positive | 11 |
highest number | 11 |
cov investigation | 11 |
cytopathic effect | 11 |
south east | 11 |
russian state | 11 |
related coronavirus | 11 |
different mers | 11 |
significant increase | 11 |
crispr cas | 11 |
two independent | 11 |
high genetic | 10 |
arabia reported | 10 |
isolates revealed | 10 |
blood products | 10 |
overcrowded emergency | 10 |
antibody specifically | 10 |
immunohistochemical staining | 10 |
emerging disease | 10 |
nucleic acids | 10 |
rna copies | 10 |
virus rna | 10 |
human health | 10 |
israel epi | 10 |
lower lung | 10 |
lassa fever | 10 |
global threat | 10 |
published studies | 10 |
infection tracked | 10 |
developed mers | 10 |
isl unitedarabemirates | 10 |
kidney cells | 10 |
fusion inhibitors | 10 |
phylogenetic trees | 10 |
neutralisation assay | 10 |
knowledge gaps | 10 |
state security | 10 |
cov pandemic | 10 |
antibody protects | 10 |
cases occurred | 10 |
control recommendations | 10 |
care setting | 10 |
study ribavirin | 10 |
endotracheal intubation | 10 |
recently emerged | 10 |
argasidae ticks | 10 |
int csr | 10 |
isl israel | 10 |
nosocomial mers | 10 |
airborne infection | 10 |
associated deaths | 10 |
medical sciences | 10 |
phase iii | 10 |
multifacility outbreak | 10 |
product development | 10 |
specific antibody | 10 |
findings suggest | 10 |
multicenter retrospective | 10 |
brain tissue | 10 |
higher mortality | 10 |
human polyclonal | 10 |
cov circulation | 10 |
private hospital | 10 |
subclinical infection | 10 |
signaling pathways | 10 |
russian far | 10 |
sat members | 10 |
people infected | 10 |
ppe use | 10 |
expressing hdpp | 10 |
analysis using | 10 |
pcr positive | 10 |
humans middle | 10 |
environmental samples | 10 |
developed fever | 10 |
health implications | 10 |
disease emergence | 10 |
jeddah outbreak | 10 |
alveolar cavities | 10 |
early identification | 10 |
insurance sector | 10 |
potential source | 10 |
patients representing | 10 |
health concern | 10 |
isl turkey | 10 |
acute febrile | 10 |
turkey epi | 10 |
research groups | 10 |
cov seroprevalence | 10 |
environmental cleaning | 10 |
adapted mers | 10 |
animal market | 10 |
novel group | 10 |
human igg | 10 |
include homologues | 10 |
patients suspected | 10 |
chest radiography | 10 |
including fever | 10 |
study provides | 10 |
immunofluorescence assay | 10 |
severe influenza | 10 |
prone positioning | 10 |
superspreading events | 10 |
sequence alignment | 10 |
therapeutic option | 10 |
major challenge | 10 |
coronavirus nsp | 10 |
coronavirus referral | 10 |
isl saudiarabia | 10 |
virus particles | 10 |
foodborne diseases | 10 |
transport medium | 10 |
google scholar | 10 |
novel corona | 10 |
potent neutralizing | 10 |
human cd | 10 |
icu stay | 10 |
armed forces | 10 |
viral vectors | 10 |
generation cases | 10 |
virus titration | 10 |
mild cases | 10 |
kalmyk republic | 10 |
throat swab | 10 |
negative controls | 10 |
potent human | 10 |
ang ii | 10 |
confirmed patients | 10 |
data indicate | 10 |
travelers returning | 10 |
three strains | 10 |
electronic medical | 10 |
preventive treatment | 10 |
south china | 10 |
health england | 10 |
putus pick | 10 |
transmission occurs | 10 |
reproductive number | 10 |
chinese horseshoe | 10 |
agriculture organization | 10 |
diseases caused | 10 |
recombinant adenovirus | 10 |
infection case | 10 |
positive samples | 10 |
unitedarabemirates epi | 10 |
erasmus medical | 10 |
korea centers | 10 |
risk groups | 10 |
sea basin | 10 |
high rates | 10 |
coronavirus quasispecies | 10 |
comprehensive review | 10 |
nasal carriage | 10 |
toscana virus | 10 |
local health | 10 |
delivering middle | 10 |
infectious respiratory | 10 |
large case | 10 |
wild carnivores | 10 |
research center | 10 |
infections hospital | 10 |
nasal epithelium | 10 |
serologic assays | 10 |
i pneumocytes | 10 |
vitro anti | 10 |
camel workers | 10 |
eastern asia | 10 |
clinical decision | 10 |
analysis revealed | 10 |
therapeutic interventions | 10 |
aedes albopictus | 10 |
oral ribavirin | 10 |
related virus | 10 |
avian coronavirus | 10 |
based assays | 10 |
every year | 10 |
us centers | 10 |
emerging viral | 10 |
virus neutralization | 10 |
food control | 10 |
immunocompromised patients | 10 |
crimean hemorrhagic | 10 |
widely used | 10 |
acid residues | 10 |
fi ndings | 10 |
took place | 10 |
outbreak investigations | 10 |
virus group | 10 |
might also | 10 |
yellow fever | 10 |
aedes mosquitoes | 10 |
rhesus monkeys | 10 |
cov research | 10 |
infection rates | 10 |
ct findings | 10 |
viral proteases | 10 |
west coast | 10 |
disease course | 10 |
may help | 10 |
syndrome generation | 10 |
virus titers | 10 |
economic development | 10 |
common respiratory | 10 |
pcr diagnosis | 10 |
viral envelope | 10 |
bibliometric analysis | 10 |
arboviral infections | 10 |
laboratory diagnosis | 10 |
known mers | 10 |
water supplies | 10 |
transmission may | 10 |
nhp models | 10 |
scientific research | 10 |
white blood | 10 |
pathogenic influenza | 10 |
coronavirus papain | 10 |
future studies | 10 |
zoonotic potential | 10 |
mers transmission | 10 |
organ dysfunction | 10 |
northern part | 10 |
cov hku | 10 |
also associated | 10 |
specifically targeting | 10 |
poor countries | 10 |
mass gathering | 10 |
two hospitals | 10 |
expressing mers | 10 |
group viruses | 10 |
virus cultured | 10 |
global technical | 10 |
rna synthesis | 10 |
bat covs | 10 |
three different | 10 |
many studies | 10 |
epidemic outbreaks | 10 |
super spreaders | 10 |
days postinoculation | 10 |
exact test | 10 |
assay specificity | 10 |
natural hosts | 10 |
infection consortium | 10 |
pooled estimate | 10 |
neutralization assay | 10 |
saudiarabia epi | 10 |
time course | 10 |
coronavirus pandemic | 10 |
least days | 10 |
university hospital | 10 |
zika virus | 10 |
antigenically related | 9 |
case patient | 9 |
immunological responses | 9 |
inhibitory concentration | 9 |
transchromosomic bovines | 9 |
new emerging | 9 |
natural disasters | 9 |
high rate | 9 |
invasive ventilation | 9 |
patient care | 9 |
mers vaccine | 9 |
study protocol | 9 |
adenovirus vector | 9 |
cov reported | 9 |
mice transgenic | 9 |
antiviral peptides | 9 |
anas platyrhynchos | 9 |
intellectual content | 9 |
fold serial | 9 |
bacillus cereus | 9 |
lethal outcomes | 9 |
young children | 9 |
detectable antibodies | 9 |
reaction assays | 9 |
basic reproduction | 9 |
will likely | 9 |
lethal respiratory | 9 |
chronic kidney | 9 |
mva based | 9 |
severe human | 9 |
less likely | 9 |
cov accessory | 9 |
day postinfection | 9 |
national institutes | 9 |
different genotypes | 9 |
sectional surveillance | 9 |
ml mers | 9 |
information age | 9 |
local customs | 9 |
dead survived | 9 |
human ace | 9 |
subgenus embecovirus | 9 |
gambian fruit | 9 |
wbc count | 9 |
natural antagonist | 9 |
ixodidae tick | 9 |
first step | 9 |
information regarding | 9 |
different species | 9 |
significantly increased | 9 |
travellers returning | 9 |
pfu ml | 9 |
ixodes ricinus | 9 |
elevated serum | 9 |
highly potent | 9 |
transmission route | 9 |
influenza vaccination | 9 |
determine whether | 9 |
research activity | 9 |
associated factors | 9 |
confi rmation | 9 |
strain isolated | 9 |
serologic studies | 9 |
ct scan | 9 |
lethal mers | 9 |
developing severe | 9 |
new strain | 9 |
hypoxemic respiratory | 9 |
infect doi | 9 |
serum creatinine | 9 |
medical history | 9 |
cellular receptor | 9 |
three novel | 9 |
unpasteurized camel | 9 |
copy number | 9 |
clinical samples | 9 |
faecal samples | 9 |
african green | 9 |
animal origin | 9 |
zoonotic viruses | 9 |
oedematous alveolar | 9 |
heart failure | 9 |
disease transmission | 9 |
adjusted odds | 9 |
clinical research | 9 |
care associated | 9 |
arbovirus infections | 9 |
preliminary epidemiological | 9 |
porcine epidemic | 9 |
genetic material | 9 |
transmission heterogeneity | 9 |
human primary | 9 |
twentieth century | 9 |
causes widespread | 9 |
important intellectual | 9 |
possibly linked | 9 |
may cause | 9 |
mers infections | 9 |
pathogenic coronaviruses | 9 |
communicable disease | 9 |
serine protease | 9 |
time frame | 9 |
days since | 9 |
will provide | 9 |
pressure rooms | 9 |
eye protection | 9 |
large proportion | 9 |
twice daily | 9 |
mammalian cells | 9 |
critical revision | 9 |
medical record | 9 |
recombinant protein | 9 |
different types | 9 |
antigenic group | 9 |
hospital staff | 9 |
highly sensitive | 9 |
prognostic factors | 9 |
cov surveillance | 9 |
commercially available | 9 |
health threat | 9 |
livestock dromedaries | 9 |
cell fusion | 9 |
one hundred | 9 |
arab region | 9 |
computed tomography | 9 |
previously published | 9 |
west african | 9 |
antiviral treatments | 9 |
species barrier | 9 |
patients without | 9 |
clinically developed | 9 |
many different | 9 |
dhori virus | 9 |
mediated entry | 9 |
additional cases | 9 |
eastern part | 9 |
known human | 9 |
coronavirus treatment | 9 |
gcc countries | 9 |
arabia epidemiological | 9 |
alveolar septum | 9 |
coronavirus clinical | 9 |
coronavirus cases | 9 |
detect mers | 9 |
bibliometric studies | 9 |
immune serum | 9 |
camel barn | 9 |
human mab | 9 |
community transmission | 9 |
assay panel | 9 |
rna detection | 9 |
abdulaziz medical | 9 |
mers pneumonia | 9 |
molecular clock | 9 |
candidate vaccines | 9 |
human interface | 9 |
dairy products | 9 |
raw camel | 9 |
nucleotide sequences | 9 |
virus vaccines | 9 |
human lung | 9 |
diagnostic test | 9 |
high morbidity | 9 |
natural history | 9 |
exposure device | 9 |
pp ab | 9 |
within hours | 9 |
human pathology | 9 |
household transmission | 9 |
virus challenge | 9 |
sialic acids | 9 |
controlled clinical | 9 |
clinical validation | 9 |
common murre | 9 |
rtpcr positive | 9 |
former ussr | 9 |
cov qatar | 9 |
recent travel | 9 |
nucleoside analogue | 9 |
molecular evolution | 9 |
ground glass | 9 |
korea transmission | 9 |
two main | 9 |
fulica atra | 9 |
second week | 9 |
blood transfusion | 9 |
emerging infections | 9 |
respiratory epithelium | 9 |
submucosal glands | 9 |
may provide | 9 |
observed among | 9 |
rbd residues | 9 |
using data | 9 |
recent outbreaks | 9 |
hospital settings | 9 |
barn owned | 9 |
drug compounds | 9 |
reported among | 9 |
may require | 9 |
developed drugs | 9 |
city health | 9 |
migrating birds | 9 |
reactors among | 9 |
biological specimens | 9 |
milk collected | 9 |
myodes glareolus | 9 |
antibody reactors | 9 |
contact investigations | 9 |
critical role | 9 |
coronavirus patients | 9 |
ill mers | 9 |
adult camels | 9 |
cases per | 9 |
surveillance system | 9 |
selective sweep | 9 |
sample originating | 9 |
time interval | 9 |
associated infection | 9 |
argas ticks | 9 |
possible genetic | 9 |
conducted using | 9 |
coronaviruses reveals | 9 |
laikipia county | 9 |
proteolytic processing | 9 |
kinetic analysis | 9 |
passive transfer | 9 |
searched pubmed | 9 |
case definitions | 9 |
like symptoms | 9 |
detected among | 9 |
farm animals | 9 |
lung samples | 9 |
antibody tests | 9 |
interspecies transmission | 9 |
virus closely | 9 |
virus evolution | 9 |
human case | 9 |
supportive therapy | 9 |
cyclophilin inhibitors | 9 |
reservoir hosts | 9 |
specific mers | 9 |
inflammatory response | 9 |
cov referral | 9 |
fusion core | 9 |
fusion peptide | 9 |
large quantities | 9 |
recent middle | 9 |
laboratory data | 9 |
applied biosystems | 9 |
global level | 9 |
insurance company | 9 |
approved drugs | 9 |
systematic reviews | 9 |
whole blood | 9 |
library identifies | 9 |
safety issues | 9 |
maximum likelihood | 9 |
informed consent | 9 |
probable transmission | 9 |
fatal human | 9 |
vaccine based | 9 |
independent states | 9 |
care units | 9 |
mers virus | 9 |
vaccine design | 9 |
infected alpacas | 9 |
corticosteroid treatment | 9 |
indirect immunofluorescence | 9 |
second case | 9 |
humans possibly | 9 |
serotine bat | 9 |
pressure operating | 9 |
structural protein | 9 |
three groups | 9 |
close relatives | 9 |
care response | 9 |
experimental transmission | 9 |
interferon antagonists | 9 |
highly conserved | 8 |
infected travellers | 8 |
environmental factors | 8 |
compound library | 8 |
novel mammalian | 8 |
affected areas | 8 |
single imported | 8 |
ribavirin interferon | 8 |
using graphpad | 8 |
amotosalen uva | 8 |
marmoset model | 8 |
term excretion | 8 |
virus among | 8 |
member states | 8 |
respiratory specimen | 8 |
using mers | 8 |
neutralization tests | 8 |
novel recombinant | 8 |
two weeks | 8 |
healthcare providers | 8 |
strict implementation | 8 |
laboratory animals | 8 |
animal populations | 8 |
initial infection | 8 |
articles published | 8 |
field studies | 8 |
often used | 8 |
ifn response | 8 |
infection treated | 8 |
infected pneumonia | 8 |
cohort studies | 8 |
population growth | 8 |
reported laboratory | 8 |
healthcare associated | 8 |
alveolar epithelium | 8 |
may increase | 8 |
one example | 8 |
vertebrate host | 8 |
outbreak member | 8 |
especially among | 8 |
cov therapies | 8 |
aedes aegypti | 8 |
initial presentation | 8 |
respir viruses | 8 |
coronavirus isolates | 8 |
severe infection | 8 |
study revealed | 8 |
secondary attack | 8 |
potential epidemiological | 8 |
exposure history | 8 |
creatinine clearance | 8 |
causing severe | 8 |
hospital contacts | 8 |
viral genomic | 8 |
red cross | 8 |
wnv strains | 8 |
organizing pneumonia | 8 |
escape mutants | 8 |
alanine aminotransferase | 8 |
probable risk | 8 |
one day | 8 |
cell activation | 8 |
mini kit | 8 |
human adenovirus | 8 |
low prevalence | 8 |
hospital room | 8 |
chinese medicine | 8 |
community case | 8 |
traditional chinese | 8 |
cov medical | 8 |
without respiratory | 8 |
nitric oxide | 8 |
antibiotic resistance | 8 |
cov pl | 8 |
first immunization | 8 |
detected mers | 8 |
pressure room | 8 |
host range | 8 |
approved compound | 8 |
patients clinical | 8 |
typhoid fever | 8 |
cellular immunogenicity | 8 |
encephalitis viruses | 8 |
susan i | 8 |
years since | 8 |
serological methods | 8 |
three patients | 8 |
receptor usage | 8 |
poor prognosis | 8 |
jordan middle | 8 |
dromedary calf | 8 |
cov isolate | 8 |
airborne routes | 8 |
goat anti | 8 |
cases middle | 8 |
several times | 8 |
acid substitutions | 8 |
noninvasive ventilation | 8 |
cov global | 8 |
one third | 8 |
influenza pandemic | 8 |
emerging viruses | 8 |
gastroenteritis virus | 8 |
segment encodes | 8 |
lung homogenates | 8 |
study using | 8 |
pediatric age | 8 |
small molecule | 8 |
aged years | 8 |
overall mortality | 8 |
german hospital | 8 |
vector borne | 8 |
neutralizing human | 8 |
vivo studies | 8 |
binding domains | 8 |
outbreak occurred | 8 |
viral infectivity | 8 |
unlike sars | 8 |
arab countries | 8 |
described elsewhere | 8 |
syndrome severe | 8 |
vitro stimulation | 8 |
host infectivity | 8 |
clinical use | 8 |
severe outcome | 8 |
replication cycle | 8 |
madinah city | 8 |
tyuleniy island | 8 |
among people | 8 |
known cases | 8 |
received ribavirin | 8 |
epidemiological status | 8 |
renal function | 8 |
central asian | 8 |
inoculated rabbits | 8 |
wash fluid | 8 |
per day | 8 |
cov plpro | 8 |
masked palm | 8 |
cell tropism | 8 |
saudi moh | 8 |
borne flaviviruses | 8 |
shedding dromedaries | 8 |
several groups | 8 |
natural host | 8 |
two hospital | 8 |
community outbreak | 8 |
van den | 8 |
clinical recovery | 8 |
associated mers | 8 |
signal peptide | 8 |
double staining | 8 |
diagnosis delay | 8 |
sars virus | 8 |
two doses | 8 |
reported direct | 8 |
insurance demand | 8 |
adverse effects | 8 |
security council | 8 |
den brand | 8 |
survival data | 8 |
nosocomial clusters | 8 |
vice versa | 8 |
rational design | 8 |
camel vaccine | 8 |
japanese pipistrelle | 8 |
based discovery | 8 |
positive result | 8 |
following mers | 8 |
med doi | 8 |
gold standard | 8 |
anthropogenic biocenoses | 8 |
health insurance | 8 |
cov disease | 8 |
clinical diagnosis | 8 |
market development | 8 |
appropriate infection | 8 |
potential role | 8 |
new human | 8 |
financial crisis | 8 |
additional data | 8 |
thermo fisher | 8 |
per patient | 8 |
otitis media | 8 |
foreign companies | 8 |
human sera | 8 |
main vector | 8 |
day incubation | 8 |
clinical forms | 8 |
identified mers | 8 |
among wild | 8 |
like cov | 8 |
therapeutic countermeasures | 8 |
immunocompromised hosts | 8 |
betacoronavirus emc | 8 |
receptor specificity | 8 |
delayed induction | 8 |
subgenomic rnas | 8 |
antimicrobial drugs | 8 |
disseminated intravascular | 8 |
genus alphacoronavirus | 8 |
several countries | 8 |
infection kinetics | 8 |
quantitative pcr | 8 |
radiological findings | 8 |
lung function | 8 |
respiratory tracts | 8 |
infection mers | 8 |
intratracheal inoculation | 8 |
reported days | 8 |
gulf countries | 8 |
fatality ratio | 8 |
ixodid ticks | 8 |
deep tracheal | 8 |
odds ratios | 8 |
exclusion criteria | 8 |
drug administration | 8 |
military medical | 8 |
female camels | 8 |
ankara delivering | 8 |
last years | 8 |
level risk | 8 |
tract disease | 8 |
poorly understood | 8 |
first isolation | 8 |
specific treatment | 8 |
igg antibody | 8 |
asymptomatic middle | 8 |
probable case | 8 |
aerosol generating | 8 |
targeting receptor | 8 |
fatal respiratory | 8 |
longitudinal study | 8 |
control implications | 8 |
requiring mechanical | 8 |
prevention control | 8 |
young camels | 8 |
online version | 8 |
inhibit sars | 8 |
developed acute | 8 |
year old | 8 |
much stronger | 8 |
acute phase | 8 |
animal nose | 8 |
recombinant virus | 8 |
drug discovery | 8 |
viruses belonging | 8 |
countries including | 8 |
well documented | 8 |
cov therapy | 8 |
rapid immunochromatographic | 8 |
novel virus | 8 |
collected according | 8 |
interim infection | 8 |
genotype i | 8 |
update middle | 8 |
batai virus | 8 |
pulmonary pathology | 8 |
epidemiologic characteristics | 8 |
clinical development | 8 |
strong neutralizing | 8 |
nauki i | 8 |
univariate analysis | 8 |
saudi intensive | 8 |
higher among | 8 |
virus outbreak | 8 |
sample collection | 8 |
culex pipiens | 8 |
may result | 8 |
face masks | 8 |
baloxavir marboxil | 8 |
camels tested | 8 |